Talk:Atezolizumab
This is the talk page for discussing improvements to the Atezolizumab article. This is not a forum for general discussion of the article's subject. |
Article policies
|
Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||
|
Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Atezolizumab.
|
Should we mention cost here and or in PD-L1 inhibitors ?
[edit]Roche therapy helps 24 percent of untreated bladder cancer patients: study says "At a list price of $12,500 per month, Tecentriq costs roughly the same as [PD-1 inhibitors] Keytruda and Bristol's rival Opdivo" - Should we mention cost here and /or in PD-L1 inhibitors ? - Rod57 (talk) 09:11, 13 June 2016 (UTC)
Compared with docetaxel chemotherapy
[edit]Immunotherapy drug gives non-small-cell lung cancer patients extra four months of life with fewer side effects compared to chemotherapy (or the Lancet source) could be mentioned. - Rod57 (talk) 13:20, 17 December 2016 (UTC)
Should distinguish the similar OAK and POPLAR trials PD-L1 Inhibitor Wins NSCLC Indication - Rod57 (talk) 13:25, 20 December 2016 (UTC)
EU approval
[edit]Also now approved (full/unconditional?) for "two types of metastatic bladder cancer" says [1] - Need EU RS - Rod57 (talk) 13:22, 1 October 2017 (UTC)
No confirmatory evidence for FDA approvals
[edit]According to FDA says Tecentriq won't lose its bladder cancer nod despite phase 3 failure, Roche reports - Lets see what the FDA say. - Rod57 (talk) 14:21, 5 October 2017 (UTC)
Name
[edit]This article should explain why this drug is named what it is. 2A04:4A43:572F:E992:0:0:2272:ABC8 (talk) 15:44, 29 August 2023 (UTC)